INTRODUCTION

Life-changing therapies for people living with serious inflammatory diseases

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of Sonelokimab, a novel investigational Nanobody® for the treatment of inflammation, to elevate outcomes for patients.

WHAT’S GOING ON

MoonLake news

05/22
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
04/22
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp
03/22
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
08/21
MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors
ABOUT US

We go
beyond

We go beyond by bringing unrivalled expertise and experience to innovate the way new treatments are developed for inflammatory diseases.
SCIENCE

We do stellar science

We apply stellar science, sponsoring innovative research work and clinical trials globally, to target inflammatory diseases with a major unmet need where Sonelokimab has the potential to transform patient outcomes.
INVESTOR RELATIONS

We unlock
value

We are unlocking the value of Sonelokimab with our ambitious Phase 2 program across lead indications for hidradenitis suppurativa, psoriatic arthritis and ankylosing spondylitis (or r-axSpA).